Chronic CPP Crystal Inflammatory Arthritis: What to Do When Methotrexate Has Not Worked
Chronic CPP crystal inflammatory arthritis is a persistent inflammatory oligoarthritis or polyarthritis. In some patients, chronic joint inflammation closely resembles rheumatoid arthritis, which can complicate recognition and management.
Previous treatment — inadequate response
When Methotrexate has not achieved the expected targets — a decrease in VAS pain, reduction in the number of swollen and tender joints, a decrease in erythrocyte sedimentation rate and C-reactive protein, and symptom improvement within the expected timeframe — a further treatment line is indicated.
Clinical Goal at This Stage
The primary objective is a meaningful reduction in the patient's global assessment VAS at 3 months, reflecting sustained control of disease activity.
Treatment approach (partial — full regimen available below)
This protocol involves targeted biologic agents that address key inflammatory pathways driving CPP crystal-related joint disease.
Full prescribing detail, sequencing, and monitoring criteria are set out in the structured regimen…
References
DOI: 10.3389/fmed.2024.1327715
- A subset of patients with CPP arthritis may present with symptoms of chronic joint inflammation that can be mistaken for RA.
- Chronic CPP crystal arthritis, on the other hand, is a chronic inflammatory oligoarthritis or polyarthritis.
- The use of tocilizumab, a monoclonal antibody targeting the IL-6 receptor, has been tested in treating persistent CPP arthritis.
- An open-label pilot study involving 11 CPPD patients with either prior treatment failure, contraindication, or intolerance to other medications, showed promising results with tocilizumab.
- Cipolletta et al. reported that in chronic CPP arthritis, the response rate to anakinra was 42.9%.
- Nevertheless, all the studies included in the analysis showed that anakinra could prevent the onset of new flares in chronic CPP arthritis.
- After 3 months, the median global assessment VAS significantly reduced from 60 to 15 (p = 0.006), and treatment efficacy was sustained during a median 10-month follow-up.
View source ↗